<DOC>
	<DOC>NCT00666458</DOC>
	<brief_summary>Saxagliptin is a new investigational medication being developed for treatment of type 2 diabetes. This study is designed to assess the efficacy and tolerability of saxagliptin in addition to metformin and compare to sitagliptin in addition with metformin.</brief_summary>
	<brief_title>18-week add-on to Metformin Comparison of Saxagliptin and Sitagliptin in Adult Patients With Type 2 Diabetes (T2D)</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Saxagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Diagnosed with type 2 diabetes Treatment with metformin alone on stable doses of 1500 mg or higher per day for at least 8 weeks Type 1 diabetes, history of diabetic ketoacidosis or hyperosmolar nonketotic coma Insulin therapy within one year Previous treatment with DPP4 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>metformin</keyword>
</DOC>